Scientists have moved one step closer to developing an effective coronavirus vaccine. Moderna and Pfizer both announced their potential vaccines have entered the final phase of testing.
Moderna, which partnered with the National Institute of Allergy and Infectious Diseases and the National Institute of Health, is recruiting 30,000 people in the United States for their trial. Half of the volunteers will receive the vaccine, while the other half will be given a placebo. They hope to have preliminary results by late fall or early winter.
"Having a safe and effective vaccine distributed by the end of 2020 is a stretch goal, but it's the right goal for the American people," Dr. Francis Collins, the director of the NIH, said in a statement.
Pfizer, which has been working with BioNTech, on a different type of vaccine, is also recruiting 30,000 volunteers from the United States, Germany, Brazil, and Argentina. They expect the third clinical phase to be completed within two months. It will take another six months to compile the results and determine if the vaccine is safe and effective.
The United States is hoping to see positive results and has already agreed to buy 100 million doses of Pfizer's vaccine if the tests go well.
Photo: Getty Images